GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » CytoSorbents Corp (NAS:CTSO) » Definitions » PS Ratio

CytoSorbents (CytoSorbents) PS Ratio : 1.26 (As of May. 05, 2024)


View and export this data going back to 2005. Start your Free Trial

What is CytoSorbents PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, CytoSorbents's share price is $0.88. CytoSorbents's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.70. Hence, CytoSorbents's PS Ratio for today is 1.26.

Good Sign:

CytoSorbents Corp stock PS Ratio (=1.26) is close to 10-year low of 1.15

The historical rank and industry rank for CytoSorbents's PS Ratio or its related term are showing as below:

CTSO' s PS Ratio Range Over the Past 10 Years
Min: 1.15   Med: 12.49   Max: 90
Current: 1.26

During the past 13 years, CytoSorbents's highest PS Ratio was 90.00. The lowest was 1.15. And the median was 12.49.

CTSO's PS Ratio is ranked better than
77.92% of 806 companies
in the Medical Devices & Instruments industry
Industry Median: 3.23 vs CTSO: 1.26

CytoSorbents's Revenue per Sharefor the three months ended in Dec. 2023 was $0.16. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.70.

Warning Sign:

CytoSorbents Corp revenue per share has been in decline over the past 3 years.

During the past 12 months, the average Revenue per Share Growth Rate of CytoSorbents was 3.30% per year. During the past 3 years, the average Revenue per Share Growth Rate was -11.80% per year. During the past 5 years, the average Revenue per Share Growth Rate was 0.10% per year. During the past 10 years, the average Revenue per Share Growth Rate was 23.00% per year.

During the past 13 years, CytoSorbents's highest 3-Year average Revenue per Share Growth Rate was 231.70% per year. The lowest was -11.80% per year. And the median was 30.05% per year.

Back to Basics: PS Ratio


CytoSorbents PS Ratio Historical Data

The historical data trend for CytoSorbents's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CytoSorbents PS Ratio Chart

CytoSorbents Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.45 7.84 4.53 2.30 1.59

CytoSorbents Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.30 5.01 5.23 2.63 1.59

Competitive Comparison of CytoSorbents's PS Ratio

For the Medical Devices subindustry, CytoSorbents's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CytoSorbents's PS Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, CytoSorbents's PS Ratio distribution charts can be found below:

* The bar in red indicates where CytoSorbents's PS Ratio falls into.



CytoSorbents PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

CytoSorbents's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=0.88/0.697
=1.26

CytoSorbents's Share Price of today is $0.88.
CytoSorbents's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.70.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


CytoSorbents  (NAS:CTSO) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


CytoSorbents PS Ratio Related Terms

Thank you for viewing the detailed overview of CytoSorbents's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


CytoSorbents (CytoSorbents) Business Description

Traded in Other Exchanges
Address
305 College Road East, Princeton, NJ, USA, 08540
CytoSorbents Corp is involves in the treatment of life-threatening conditions in the intensive care (ICU) and cardiac surgery using blood purification via proprietary polymer adsorption technology. It has a number of products commercialized and in development based on this technology platform.
Executives
Edward Raymond Jones director 70 HOGAN LANE, AMBLER PA 19002
Kathleen P. Bloch officer: Chief Financial Officer 3 PERSHING COURT, NORTH BRUNSWICK NJ 08902
Vincent Capponi officer: Chief Operating Officer MEDASORB TECHNOLOGIES, 7 DEER PARK DRIVE, SUITE K, MONMOUTH JUNCTION NJ 08852
Phillip P. Chan director, officer: President and CEO 1001 BRIGGS ROAD, SUITE 280, MOUNT LAUREL NJ 08054
Efthymios Deliargyris officer: Chief Medical Officer C/O PLX PHARMA,INC.8285 EL RIO STREET, SUITE 210, HOUSTON TX 77054
Jiny Kim director C/O CYTOSORBENTS CORPORATION, 7 DEER PARK DRIVE, SUITE K, MONMOUTH JUNCTION NJ 08852
Alan D. Sobel director 293 EISENHOWER PARKWAY, LIVINGSTON NJ 07039
Michael G. Bator director C/O CYTOSORBENTS CORP., 7 DEER PARK DR., SUITE K, MONMOUTH JUNCTION NJ 08852
Alex D'amico officer: Chief Financial Officer 10 EAST PASSAIC AVENUE, UNIT C-2, NUTLEY NJ 07110
Al Kraus director MEDASORB TECHNOLOGIES, 7 DEER PARK DRIVE, SUITE K, MONMOUTH JUNCTION NJ 08852
Eric R. Mortensen officer: Chief Medical Officer C/O CYTOSORBENTS CORPORATION, 7 DEER PARK DRIVE, SUITE K, MONMOUTH JUNCTION NJ 08852
Njtc Investment Fund, Lp 10 percent owner 1001 BRIGGS ROAD, SUITE 280, MOUNT LAUREL NJ 08054
Robert Shipley 10 percent owner 9 NOBLE ROAD, NOGALES AZ 85621
Ronald Berger officer: See Remarks 7 DEERPARK DRIVE, STE K, MONMOUTH JUNCTION NJ 08852
Thomas Bocchino officer: Chief Financial Officer C/O CYTOSORBENTS CORP., 7 DEER PARK DRIVE, SUITE K, MONMOUTH JUNCTION NJ 08852